DUEXIS Drug Patent Profile

Which patents cover Duexis, and when can generic versions of Duexis launch?

Duexis is a drug marketed by Horizon and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

DrugPatentWatch^® Generic Entry Outlook for Duexis

There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for DUEXIS

International Patents:	25
US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DUEXIS

Paragraph IV (Patent) Challenges for DUEXIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUEXIS	Tablets	famotidine; ibuprofen	800 mg/26.6 mg	022519	1	2011-12-06

US Patents and Regulatory Information for DUEXIS

DUEXIS is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,067,451		Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,309,127		Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,501,228

International Patents for DUEXIS

See the table below for patents covering DUEXIS around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E539747
Australia	2006269894
Australia	2007275360

Last updated: February 16, 2026

What Is the Current Investment Landscape for DUEXIS?

DUEXIS, marketed by Horizon Pharma (now Horizon Therapeutics), is an NSAID-based combination therapy approved for osteoarthritis pain, rheumatoid arthritis, and gout. The drug combines ibuprofen (600 mg) and famotidine (10 mg), aiming to provide effective pain relief with reduced gastrointestinal side effects associated with NSAIDs.

The drug's market presence is primarily in the U.S., with initial approval in 2013. Its sales peaked in 2017 at approximately $449 million but declined afterward due to loss of exclusivity, competition, and pricing pressures. The COVID-19 pandemic also affected demand channels, notably impacting prescription volumes.

Market size estimates: The U.S. osteoarthritis and rheumatoid arthritis markets combined account for over $10 billion annually, with NSAID treatments representing a substantial share. DUEXIS's niche is focused on patients who require NSAIDs but are at high risk for gastrointestinal complications, limiting its target demographic amidst competition.

Investment outlook: Risks stem from patent expirations, generic competition, and shifts toward biosimilars or alternative therapies. Opportunities include potential line extensions or combination formulations; however, the current revenue trajectory indicates declining momentum.

How Do the Fundamentals of DUEXIS Stand?

Patent and Regulatory Status:
DUEXIS's patent protections expired in 2019, opening the door for generic competition. The introduction of generic ibuprofen and famotidine options significantly eroded market share. The FDA-approved label remains stable, but lower-priced generics have taken a considerable portion of prescriptions.

Sales and Revenue Trends:
Horizon Therapeutics reported DUEXIS sales declining substantially post-2019, with revenues dropping from peak levels. In 2021, U.S. sales of the product decreased by approximately 60% year-over-year, reflecting generic penetration and prescriber preference shifts.

Market Penetration and Competition:
Main competitors include OTC NSAIDs like ibuprofen, naproxen, and prescription NSAIDs without added gastroprotection. Other branded products targeting similar indications include Celebrex (celecoxib), which offers selective COX-2 inhibition, potentially with better gastrointestinal safety, but at higher cost.

Pricing and Reimbursement Dynamics:
Insurance reimbursements favor generics, limiting DUEXIS's pricing power. Despite its branded status, payers increasingly favor cheaper alternatives, constraining profit margins.

Pipeline and Development:
There are no significant indications or line extensions under development for DUEXIS. Horizon's pipeline has shifted focus toward biologics and specialty therapeutics, reducing resource allocation to this product.

What Are the Key Risks and Opportunities?

Risks:

• Patent expiry leading to generic erosion.
• Intense price competition from OTC and prescription generics.
• Limited upcoming innovations or line extensions.
• Market share losses due to the rise of COX-2 inhibitors with better safety profiles.

Opportunities:

• Potential for new dosing formulations or combination therapies to regain market share.
• Expanding into markets outside the U.S., where patent protections may remain valid.
• Leveraging brand recognition with targeted physician education on GI safety profiles.

What Are Investment Strategies and Considerations?

Investors should scrutinize the following factors:

• The extent of generic competition's impact on sales revenue.
• Horizon's broader strategic focus away from DUEXIS toward high-growth biologics and specialty drugs.
• The presence of any ongoing legal challenges or patent litigation that could extend exclusivity.
• Pipeline updates for related products in gastrointestinal or pain management spaces.

Potential valuation impacts include the declining revenues and the absence of further patent protections. Valuations must incorporate the churn from brand to generic sales, with expectations for near-term revenue declines.

Key Takeaways

• DUEXIS's patent expiration in 2019 triggered significant sales decline.
• Competition from generics and OTC alternatives limited pricing power and market share.
• No pipeline or line extension strategies are underway, reducing future growth prospects.
• The drug's primary market is the U.S.; expansion opportunities are limited without regulatory or patent protections.
• Horizon’s strategic focus has shifted away from DUEXIS toward higher-margin biologic therapeutics.

FAQs

1. How long did DUEXIS maintain patent exclusivity?
DUEXIS’s patents expired in 2019, after which generic versions entered the market.

2. What are the main competitors for DUEXIS?
Generic ibuprofen and famotidine, OTC NSAIDs, and COX-2 inhibitors like Celebrex.

3. Has Horizon’s sales strategy changed regarding DUEXIS?
Yes, Horizon has shifted focus toward biologics and specialty therapeutics, reducing efforts on DUEXIS.

4. Are there any ongoing legal protections extending DUEXIS’s market life?
No current patents or legal protections extend DUEXIS’s market exclusivity.

5. Could DUEXIS regain market share?
Limited prospects, barring significant innovation or regulatory changes, due to strong generic competition.

---

References:
[1] Horizon Therapeutics Financial Reports, 2021-2022.
[2] U.S. Food & Drug Administration (FDA), Drug Approvals and Patent Status.
[3] IQVIA, Prescription Data Insights, 2021-2022.